TriSalus Life Sciences (TLSI) EBIAT (2022 - 2025)
Historic EBIAT for TriSalus Life Sciences (TLSI) over the last 4 years, with Q3 2025 value amounting to -$10.8 million.
- TriSalus Life Sciences' EBIAT fell 35064.61% to -$10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$39.6 million, marking a year-over-year increase of 2877.86%. This contributed to the annual value of -$30.0 million for FY2024, which is 4938.77% up from last year.
- Per TriSalus Life Sciences' latest filing, its EBIAT stood at -$10.8 million for Q3 2025, which was down 35064.61% from -$8.3 million recorded in Q2 2025.
- TriSalus Life Sciences' EBIAT's 5-year high stood at $2.8 million during Q1 2022, with a 5-year trough of -$35.6 million in Q4 2023.
- Over the past 4 years, TriSalus Life Sciences' median EBIAT value was -$8.3 million (recorded in 2025), while the average stood at -$9.6 million.
- Examining YoY changes over the last 5 years, TriSalus Life Sciences' EBIAT showed a top increase of 8239.22% in 2023 and a maximum decrease of 68560.77% in 2023.
- TriSalus Life Sciences' EBIAT (Quarter) stood at -$22.5 million in 2022, then plummeted by 58.1% to -$35.6 million in 2023, then soared by 71.64% to -$10.1 million in 2024, then fell by 6.95% to -$10.8 million in 2025.
- Its EBIAT was -$10.8 million in Q3 2025, compared to -$8.3 million in Q2 2025 and -$10.4 million in Q1 2025.